KLRS Stock Analysis: Buy, Sell, or Hold?
KLRS - Kalaris Therapeutics, Inc. Common Stock
$5.30
-0.09 (-1.67%)
▼
5d:
-18.46%
30d:
-49.33%
90d:
-42.73%
WAIT
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 13, 2026
Get Alerted When KLRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: KLRS is down 18.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: KLRS is down 18.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: KLRS is currently trading at $5.30, which is considered oversold relative to its 30-day fair value range of $6.79 to $10.42.
Technical Outlook: Technically, KLRS is in a uptrend. The price is currently testing key support at $5.24. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.33 (+283.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KLRS is in a uptrend. The price is currently testing key support at $5.24. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.33 (+283.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$6.79 -
$10.42
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 283.6% below Wall St target ($20.33)
- WARNING: Recommendation downgraded due to -18.5% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$6.79 -
$10.42
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$5.24
Resistance Level
$9.29
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.65
Wall Street Target
$20.33
(+283.6%)
Share & Embed Analysis
Last updated: March 31, 2026 5:30 AM ET
Data refreshes hourly during market hours. Next update: 6:30 AM
Data refreshes hourly during market hours. Next update: 6:30 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KLRS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Srinivas Akkaraju
BUY
479847 shares
2025-12-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 54 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 51 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 50 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 44 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 54 HOLD |
